‘Weekend warriors’ with diabetes have a 33% lower risk of cardiovascular mortality
Peer-Reviewed Publication
Updates every hour. Last Updated: 3-Aug-2025 08:11 ET (3-Aug-2025 12:11 GMT/UTC)
Akesis, Inc. (Akesis), a leader in cutting-edge radiation oncology technology, has formed a groundbreaking collaboration with University Hospitals Seidman Cancer Center, a nationally recognized cancer care institution in Cleveland, Ohio. Through this alliance, UH Seidman Cancer Center becomes the first medical center in the United States to implement the innovative Akesis Galaxy RTi device for patient treatments, while also serving as the flagship site for research and clinical demonstration of this advanced technology.
Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected, which further weakens the body. This wasting syndrome, known as cachexia, affects around half of all cancer patients. It is a major cause of therapy resistance, complications, and increased mortality. Researchers from Helmholtz Munich, in collaboration with Heidelberg University Hospital, the Technical University of Munich, and the German Center for Diabetes Research, have now identified a previously overlooked driver of cachexia: the liver. It responds systemically to tumors in other organs – such as the intestine or pancreas – and contributes to tissue wasting by releasing specific signaling molecules.
The application of CAR-T cell therapy against solid tumors is often hindered by the dense and rigid tumor extracellular matrix (ECM). While combining CAR-T with hyaluronidase (HAase) to reduce ECM is apparent, the efficacy is limited because of low accumulation and penetration efficiency of HAase inside the tumor tissue. Herein, the stimuli-responsive HAase-loaded nanogels (H-NGs) which are conjugated on the surface of CAR-T cells were designed for synergistically improving HAase accumulation, ECM degradation and CAR-T cell efficacy. The conjugation of H-NGs on the T cell surface was achieved through metabolic oligosaccharide engineering (MOE) in a semi-quantitatively controlled manner. Intravenous injection of H-NGs armed CAR-T cells resulted in more ECM degradation than co-injection of CAR-T cells and free H-NGs, leading to an 83.2% tumor inhibition rate and relieves tumor suppressive microenvironment in the Raji solid tumor model. Proteomic analysis of the harvested tumor tissues indicated that the combining of H-NGs and CAR-T cell collaboratively reduces cell adhesion and enhanced leukocyte transendothelial migration. Overall, this work simultaneously boosts the efficacy of hyaluronidase and CAR-T cells in combating solid tumor, which has broad application potential in cancer combination therapy.
Inspired by the reptiles’ grippy toes, researchers have developed an ultra-sticky material that adheres to tumors, delivering targeted chemotherapy for days.
Researchers at the University of Oxford and Nanyang Technological University, Singapore (NTU Singapore) have uncovered the mechanism by which cells identify and repair a highly toxic form of DNA damage that causes cancer, neurodegeneration, and premature ageing. The findings, published in Nucleic Acids Research, reveal how DNA-protein crosslinks (DPCs) – harmful DNA lesions induced by chemotherapy, formaldehyde, and UV exposure – are recognised and broken down by SPRTN, a key repair enzyme. The research team discovered a new region within SPRTN that enables it to selectively target DPC lesions, increasing its repair activity 67-fold while leaving surrounding structures unharmed.